BACKGROUND: Noninvasive fibrosis markers are routinely used in patients with liver disease. Magnetic resonance elastography (MRE) is recognized as a highly accurate methodology, but a reliable blood test for fibrosis would be useful. We examined performance characteristics of the Enhanced Liver Fibrosis (ELF) Index compared to MRE in a cohort including those with HCV, HIV, and HCV/HIV. METHODS: Subjects enrolled in the Miami Adult Studies on HIV (MASH) cohort underwent MRE and blood sampling. The ELF Index was scored and receiver-operator curves constructed to determine optimal cutoff levels relative to performance characteristics. Cytokine testing was performed to identify new markers to enhance noninvasive marker development. RESULTS: The ELF Index was determined in 459 subjects; more than half were male, non-white, and HIV-infected. MRE was obtained on a subset of 283 subjects and the group that had both studies served as the basis of the receiver-operator curve analysis. At an ELF Index of > 10.633, the area under the curve for cirrhosis (Metavir F4, MRE > 4.62 kPa) was 0.986 (95% CI 0.994-0.996; p < 0.001) with a specificity of 100%. For advanced fibrosis (Metavir F3/4), an ELF cutoff of 10 was associated with poor sensitivity but high specificity (98.9%, 95% CI 96.7-99.8%) with an AUC of 0.80 (95% CI 0.749-0.845). ELF Index performance characteristics exceeded FIB-4 performance. HCV and age were associated with increased fibrosis (p < 0.05) in a multivariable model. IP-10 was found to be a promising biomarker for improvement in noninvasive prediction algorithms. CONCLUSIONS: The ELF Index was a highly sensitive and specific marker of cirrhosis, even among HIV-infected individuals, when compared with MRE. IP-10 may be a biomarker that can enhance performance characteristics further, but additional validation is required.
BACKGROUND: Noninvasive fibrosis markers are routinely used in patients with liver disease. Magnetic resonance elastography (MRE) is recognized as a highly accurate methodology, but a reliable blood test for fibrosis would be useful. We examined performance characteristics of the Enhanced Liver Fibrosis (ELF) Index compared to MRE in a cohort including those with HCV, HIV, and HCV/HIV. METHODS: Subjects enrolled in the Miami Adult Studies on HIV (MASH) cohort underwent MRE and blood sampling. The ELF Index was scored and receiver-operator curves constructed to determine optimal cutoff levels relative to performance characteristics. Cytokine testing was performed to identify new markers to enhance noninvasive marker development. RESULTS: The ELF Index was determined in 459 subjects; more than half were male, non-white, and HIV-infected. MRE was obtained on a subset of 283 subjects and the group that had both studies served as the basis of the receiver-operator curve analysis. At an ELF Index of > 10.633, the area under the curve for cirrhosis (Metavir F4, MRE > 4.62 kPa) was 0.986 (95% CI 0.994-0.996; p < 0.001) with a specificity of 100%. For advanced fibrosis (Metavir F3/4), an ELF cutoff of 10 was associated with poor sensitivity but high specificity (98.9%, 95% CI 96.7-99.8%) with an AUC of 0.80 (95% CI 0.749-0.845). ELF Index performance characteristics exceeded FIB-4 performance. HCV and age were associated with increased fibrosis (p < 0.05) in a multivariable model. IP-10 was found to be a promising biomarker for improvement in noninvasive prediction algorithms. CONCLUSIONS: The ELF Index was a highly sensitive and specific marker of cirrhosis, even among HIV-infected individuals, when compared with MRE. IP-10 may be a biomarker that can enhance performance characteristics further, but additional validation is required.
Authors: Richard K Sterling; Eduardo Lissen; Nathan Clumeck; Ricard Sola; Mendes Cassia Correa; Julio Montaner; Mark S Sulkowski; Francesca J Torriani; Doug T Dieterich; David L Thomas; Diethelm Messinger; Mark Nelson Journal: Hepatology Date: 2006-06 Impact factor: 17.425
Authors: Julie Parkes; Paul Roderick; Scott Harris; Christopher Day; David Mutimer; Jane Collier; Martin Lombard; Graeme Alexander; John Ramage; Geoffrey Dusheiko; Mark Wheatley; Carol Gough; Alastair Burt; William Rosenberg Journal: Gut Date: 2010-07-30 Impact factor: 23.059
Authors: Flavia F Fernandes; Maria L Ferraz; Luiz E Andrade; Alessandra Dellavance; Carlos Terra; Gustavo Pereira; João L Pereira; Frederico Campos; Fátima Figueiredo; Renata M Perez Journal: J Clin Gastroenterol Date: 2015-03 Impact factor: 3.062
Authors: Hadrien A Dyvorne; Guido H Jajamovich; Octavia Bane; M Isabel Fiel; Hsin Chou; Thomas D Schiano; Douglas Dieterich; James S Babb; Scott L Friedman; Bachir Taouli Journal: Liver Int Date: 2016-02-07 Impact factor: 5.828
Authors: Marija Zeremski; Lydia M Petrovic; Luis Chiriboga; Queenie B Brown; Herman T Yee; Milan Kinkhabwala; Ira M Jacobson; Rositsa Dimova; Marianthi Markatou; Andrew H Talal Journal: Hepatology Date: 2008-11 Impact factor: 17.425
Authors: Meng Yin; Jayant A Talwalkar; Kevin J Glaser; Armando Manduca; Roger C Grimm; Phillip J Rossman; Jeff L Fidler; Richard L Ehman Journal: Clin Gastroenterol Hepatol Date: 2007-10 Impact factor: 11.382
Authors: Siddharth Singh; Sudhakar K Venkatesh; Zhen Wang; Frank H Miller; Utaroh Motosugi; Russell N Low; Tarek Hassanein; Patrick Asbach; Edmund M Godfrey; Meng Yin; Jun Chen; Andrew P Keaveny; Mellena Bridges; Anneloes Bohte; Mohammad Hassan Murad; David J Lomas; Jayant A Talwalkar; Richard L Ehman Journal: Clin Gastroenterol Hepatol Date: 2014-11-20 Impact factor: 11.382
Authors: Thomas Karlas; Arne Dietrich; Veronica Peter; Christian Wittekind; Ralf Lichtinghagen; Nikita Garnov; Nicolas Linder; Alexander Schaudinn; Harald Busse; Christiane Prettin; Volker Keim; Michael Tröltzsch; Tatjana Schütz; Johannes Wiegand Journal: PLoS One Date: 2015-11-03 Impact factor: 3.240
Authors: Kenneth E Sherman; Heidi L Meeds; Susan D Rouster; Enass A Abdel-Hameed; Jacqueline Hernandez; Javier Tamargo; Jun Chen; Richard L Ehman; Marianna Baum Journal: Open Forum Infect Dis Date: 2021-04-22 Impact factor: 3.835
Authors: Javier A Tamargo; Kenneth E Sherman; Adriana Campa; Sabrina S Martinez; Tan Li; Jacqueline Hernandez; Colby Teeman; Raul N Mandler; Jun Chen; Richard L Ehman; Marianna K Baum Journal: Am J Clin Nutr Date: 2021-03-11 Impact factor: 8.472
Authors: Daniel Bradshaw; Yvonne Gilleece; Sumita Verma; Iga Abramowicz; Stephen Bremner; Nicky Perry Journal: BMJ Open Date: 2020-07-06 Impact factor: 2.692